Bhringraj: Oils, Formulations and Safety
Bhringraj has a long food and topical record and no notable toxicity signal. That deserves saying first and plainly, because a safety page written to sound cautious is as misleading as a sales page written to sound safe. There is no credible reason to treat scalp application of a bhringraj oil as a risky act.
There are, however, four genuine issues, and they are specific rather than generic. It is an Asteraceae plant applied repeatedly to skin, which is the classic pattern for contact sensitisation. Animal work reports glucose-lowering and thyroid-hormone effects, which matters to people on medication for either. Pregnancy data are absent and the plant is a phytoestrogen class member. And imported Ayurvedic products are a documented heavy-metal problem as a category — a concrete, actionable warning that has nothing to do with the botany. This page also lists, deliberately, the hazards bhringraj does not have, because a reader arriving from other herb pages may reasonably wonder.
Table of Contents
- How Bhringraj Taila Is Actually Made
- Product Forms and What Varies Between Them
- How a Scalp Oil Is Used in Practice
- Contact Dermatitis and the Asteraceae Problem
- Thiophenes and Sun Exposure
- Blood Sugar and Thyroid: Animal Signals Worth Knowing
- Interactions, Ranked by How Much Is Known
- Pregnancy, Breastfeeding and Children
- Heavy Metals in Imported Ayurvedic Products
- Hazards Bhringraj Does Not Have
- What We Do Not Know
- Key Research Papers
- Connections
- Featured Videos
How Bhringraj Taila Is Actually Made
Understanding the preparation explains most of what follows, including why the rodent studies may not describe what is in the bottle.
A classical Ayurvedic medicated oil (taila) is not an infusion in the herbal-tea sense. It is a controlled, prolonged, hot fat extraction with three components:
- Sneha — the fat. For bhringraj taila this is sesame oil in the classical texts, coconut oil in most South Indian and modern commercial practice.
- Kalka — a wet paste of the herb, ground fine.
- Drava — the liquid: the fresh plant's expressed juice (svarasa), or a decoction, sometimes buttermilk.
These are simmered together until the water phase has driven off entirely and the fat has taken up what it can. The traditional endpoint tests (sneha siddhi lakshana) are sensory and remarkably practical — the paste residue rolls between the fingers without sticking, froth subsides, a drop crackles rather than spits when thrown on fire. Practitioners distinguish soft, medium and hard degrees of cooking (mridu, madhyama, khara paka) for different intended uses.
The chemistry consequence is the important part. An oil-phase extraction preferentially captures fat-soluble constituents — coumestans to some extent, sterols, thiophenes — and largely leaves behind the water-soluble fraction, notably the ecliptasaponins and eclalbasaponins and the flavonoid glycosides. Prolonged heating also degrades heat-labile compounds. So a taila is chemically not the plant. It is a selected, partly heat-altered subset of it, at a yield nobody states on the label.
One honest point in the traditional preparation's favour. The 2008 rat study used a petroleum-ether extract among others — a non-polar solvent, so its active fraction is broadly the same fat-soluble fraction an oil would pick up. In that study, petroleum ether and ethanol extracts were mixed into an oily, water-in-oil cream and applied to shaved rat skin; the time for hair growth to start was “significantly reduced to half” compared with control animals, the 5% petroleum-ether cream gave 69 ± 4 hair follicles in the growth (anagen) phase against 47 ± 13 in controls, and the 2% and 5% petroleum-ether creams did better than the comparison treatment, 2% minoxidil solution. The oily cream base makes the tested form closer still to a taila. That is the one place where the usual "the studies used a different solvent" objection actually points towards the traditional preparation instead of against it. It remains an argument about chemical plausibility, not evidence in a person, and it is worth stating because a page that only ever lists objections is no more trustworthy than one that only lists benefits.
Product Forms and What Varies Between Them
- Bhringraj oil (taila) — the dominant commercial form and the only one most Western buyers meet. Quality varies enormously. A genuine medicated oil is dark green-brown, smells strongly and unpleasantly herbal, and lists Eclipta high in the ingredients. Products at the other end are a base oil with a token extract, added colour and fragrance. Nothing on a retail label states wedelolactone content, and no published survey of marker content across commercial bhringraj oils is cited here because none is being relied on.
- A multi-herb hair oil in a human trial — in a 2026 randomized, double-blind study, 78 participants aged 18–55 with androgenetic alopecia, hair fall and greying were assigned to a classical Ayurvedic multi-herb hair oil (Neeli Bhringadi), the oil plus 5% minoxidil, or 5% minoxidil alone for 120 days; 75 completed the study (25 per group). All groups improved significantly compared with their own starting point. The paper reports changes from baseline, there was no plain-oil or placebo group, and the oil contains several herbs, so the result cannot be assigned to Eclipta alone.
- Dried herb powder (churna) — milled aerial parts, used internally and as a scalp paste mixed with water, buttermilk or yoghurt. Traditional internal practice is roughly 1–3 g daily.
- Fresh juice (svarasa) — the classical internal form, around 10–20 mL with honey. Only practical where the plant grows.
- Decoction — the Chinese form for mo han lian, conventionally 9–15 g of dried herb daily, essentially always within a multi-herb formula.
- Er Zhi Wan — the classical mo han lian plus Ligustrum lucidum pill, widely manufactured. A two-herb product; nothing in its effects attributes to Eclipta alone.
- Capsules — usually plain dried-herb powder with no marker assay. Extracts standardised to wedelolactone exist but are uncommon.
- Shampoos and cosmetic blends — contact time is minutes, and the Eclipta content is typically far down the ingredient list. Whatever the plant may or may not do, a rinse-off product is the least likely form to do it.
On the wide dose gap: Ayurvedic practice uses roughly 1–3 g of powder daily and Chinese practice 9–15 g of dried herb in decoction — a severalfold difference. That gap exists because neither figure came from a dose-finding study. They are two traditions of practice, and both are historical convention rather than a therapeutic dose. This page will not print a recommended dose, because there is no human dose-finding data to derive one from, and a confident number would be a guess dressed as guidance.
How a Scalp Oil Is Used in Practice
Descriptive, not prescriptive — this is what traditional and current practice looks like, with the sensible precautions attached.
- A patch test comes first. A coin-sized amount goes on the inner forearm, is left on, and is checked at 48 hours and again at 96 hours, before the first whole-scalp application and again after a change of brand, because the reaction risk lives partly in the fragrance and preservatives rather than the herb.
- The oil goes on the scalp, not just the hair. Traditional use is a scalp massage; the hair shaft is dead keratin and nothing applied to it is being absorbed.
- It is left on 30–60 minutes, or overnight, then washed out, typically one to three times a week.
- Staining is expected. The sap oxidises blue-black; that is the plant's signature property. Towels, pillowcases and light or grey hair will pick up colour. Any darkening of grey hair is this — a deposited pigment that washes out, not repigmentation. The hair-growth page explains why biological repigmentation is not on the table.
- Broken, inflamed or infected skin is the exception. Compromised skin absorbs more and sensitises more readily.
- Washing it out before extended sun exposure is a free precaution — see the thiophene section below.
- Any change takes about six months to declare itself, and shedding is a better gauge than feel. Hair grows about a centimetre a month, and telogen effluvium recovers on its own over six to nine months, so short-term impressions are unreliable in both directions.
Contact Dermatitis and the Asteraceae Problem
This is the realistic adverse event, and it follows from three facts stacking rather than from anything unusual about the plant.
Fact one: the daisy family is a major source of contact allergens. Compositae dermatitis is a well-characterised entity, and the sensitising chemistry is largely sesquiterpene lactones. Paulsen's work on contact sensitisation from Compositae-containing herbal remedies and cosmetics in Contact Dermatitis — PubMed PMID: 12492516 — is the standard reference for the herbal-product side of it. Patch-test clinics screen for it with a sesquiterpene lactone mix and often a Compositae mix.
Fact two: Eclipta is Asteraceae. So cross-reactivity is plausible for anyone already sensitive to ragweed, chrysanthemum, feverfew, chamomile, marigold, arnica, dandelion, artichoke, lettuce or milk thistle. For anyone whom a chamomile cream or an arnica gel has ever given a rash, this plant is a plausible suspect.
Fact three: the exposure pattern is the sensitising one. Repeated, prolonged, occluded application of a plant preparation to the same area of skin over months is textbook allergic-contact-sensitisation exposure. That is exactly what a weekly overnight scalp oil is.
What a reaction looks like. Not immediate stinging — allergic contact dermatitis is delayed, appearing 12–72 hours after exposure, as itch, redness, small bumps or weeping, often at the hairline, behind the ears, on the neck and eyelids where oil runs rather than on the scalp itself. It typically appears after a period of uneventful use, which is why people rarely suspect the product they have been happily using. See contact dermatitis for the full picture.
Attribution takes care. A reaction to a commercial bhringraj oil may be to the Eclipta, to added fragrance, to a preservative, or to a coconut-derived surfactant. That distinction matters because it decides whether the whole plant family is off-limits or just that bottle, and only patch testing with the individual components can settle it.
The diagnosis matters too. An itchy, flaking scalp that started before the oil is more likely seborrheic dermatitis or scalp psoriasis, both of which have real treatments and neither of which improves with an occlusive oil.
Thiophenes and Sun Exposure
Like many Asteraceae, Eclipta contains polyacetylenic thiophenes, chiefly α-terthienyl and relatives, concentrated in the roots. α-Terthienyl is a documented laboratory photosensitiser: under near-ultraviolet light it generates reactive oxygen species, which is why it has been studied as a natural larvicide. The class can be surveyed at α-terthienyl phototoxicity.
What that does and does not justify. The molecule's photoactivity is real. Whether it is clinically relevant at whatever concentration survives into a diluted, aerial-part-based hair oil is unknown, and this page has found no case reports of phototoxic reactions to bhringraj oil. Two honest statements at once: there is a chemically plausible mechanism, and there is no documented clinical event. The proportionate response is a free precaution rather than a warning — washing the oil out before hours in strong sun, rather than wearing it to the beach. That costs nothing and does not require the hazard to be established.
Blood Sugar and Thyroid: Animal Signals Worth Knowing
Two animal findings that belong in a safety section rather than a benefits list, because in both cases the person most affected is someone already taking a drug that does the same thing.
Glucose. Rodent studies report hypoglycaemic and antihyperglycaemic activity for Eclipta extracts; see Eclipta hypoglycaemic studies. The magnitude in humans is unmeasured and may well be nil. But an unquantified glucose-lowering effect is a genuine consideration for anyone on insulin or a sulfonylurea, where the failure mode is hypoglycaemia rather than a lost benefit. The practical point is unglamorous: insulin and sulfonylureas already lower blood sugar, and glucose readings, especially in the first couple of weeks of an oral bhringraj preparation, are what would show an added effect.
Thyroid. Rodent work has reported changes in circulating thyroid hormone concentrations after administration of Eclipta leaf extract. This page does not name the authors, journal or direction of effect, because the primary metadata could not be verified from here and asserting it would be exactly the error this site's citation rule exists to prevent; the current state can be seen at Eclipta and thyroid hormones in mice. What follows from it is modest: for anyone on levothyroxine or an antithyroid drug who starts a daily oral preparation, the next routine thyroid-function test is what would show whether anything has changed. See thyroid-stimulating hormone (TSH) and hypothyroidism.
Neither of these is a documented harm from the plant. Both are cases where, for a person on a narrow-margin drug, a measurement shows what an assumption cannot.
Interactions, Ranked by How Much Is Known
Start with the translation that most product pages get backwards. "No known interactions" does not mean interactions have been looked for and not found. It means no interaction study exists. For bhringraj that is the literal situation: there is no human pharmacokinetic study, no cytochrome-P450 inhibition or induction data, no P-glycoprotein data, no drug-interaction trial. Everything below is inference from chemistry and animal work, and it is labelled as such.
- Documented human interactions: none. Not "none exist" — none have been studied.
- Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants, clopidogrel, daily aspirin). The plant has a traditional haemostatic indication in Chinese medicine, and an in vitro literature on platelets and coagulation that disagrees with itself — results point in both directions depending on extract and assay. Coumestans are relatives of coumarins, but anticoagulant activity requires the 4-hydroxycoumarin dimer structure of warfarin and dicoumarol, which wedelolactone does not have; so the chemistry neither predicts nor excludes an effect. An unknown direction of effect is the worst case for a narrow-therapeutic-index drug: with warfarin, direct oral anticoagulants or clopidogrel, nobody knows whether oral bhringraj would raise or lower bleeding risk. The convention for herbs of uncertain clotting effect is to stop oral use around two weeks before planned surgery.
- Glucose-lowering drugs — additive hypoglycaemia is plausible on rodent data; glucose readings would show it.
- Thyroid medication — unquantified animal signal; the next routine thyroid-function test would show a change.
- Hormone-sensitive conditions. Coumestans are a phytoestrogen class; coumestrol, the archetype, binds oestrogen receptors with meaningful affinity. Wedelolactone's own oestrogenic potency is weak and poorly quantified — see coumestans as phytoestrogens. Until it is quantified, concentrated oral extracts are an unknown quantity for people with oestrogen-receptor-positive breast cancer, endometrial cancer, endometriosis or uterine fibroids. Almost nobody mentions this, and it applies to the class rather than to a measured property of this plant.
- Immunosuppressants, transplant drugs, antiretrovirals, antiepileptics — no data either way. Where a drug has a narrow margin and the herb has no P450 data, nothing is known about what a combination does, and the narrow margin is what makes that unknown matter.
- Topical use. Systemic interaction from a scalp oil is unlikely on first principles, and there is no dermal absorption data for any Eclipta constituent to confirm or refute that.
Pregnancy, Breastfeeding and Children
Oral use in pregnancy: no safety data, and three reasons for concern, none of them a documented harm:
- There is no reproductive toxicology programme and no human pregnancy data for this plant.
- Some traditional sources associate it with menstrual stimulation, which is the sort of reputation that does not settle the question but does raise it.
- The coumestan phytoestrogen question is unresolved, and hormonal activity is exactly what one would not want unquantified during a pregnancy.
Breastfeeding: no data on transfer into milk. Children: no dose-finding, no paediatric safety data; and if the product is an imported Ayurvedic preparation, the heavy-metal concern below weighs more heavily for a child than an adult because of both dose-per-weight and neurodevelopmental susceptibility.
Topical use of a plain oil in these groups is a lower-stakes decision, but "no data" is still the accurate description, and a patch test still applies.
Heavy Metals in Imported Ayurvedic Products
This is the most concrete, actionable warning on the page, and it is not about the plant at all — it is about a product category.
The evidence. Two surveys in JAMA established the problem. Saper and colleagues reported the heavy-metal content of Ayurvedic herbal medicine products sold in the Boston area in 2004, and then lead, mercury and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the internet in 2008. A meaningful fraction of sampled products contained detectable lead, mercury or arsenic, some at levels that would exceed accepted intake limits with regular use. Case reports of lead poisoning traced to Ayurvedic remedies appear in the clinical literature independently — see lead poisoning from traditional remedies.
What the two surveys found. The 2004 survey found heavy metals in 14 (20%) of 70 Ayurvedic herbal medicine products made in South Asia and sold in Boston-area stores; each of those 14, if taken as the manufacturer recommended, could give heavy-metal intakes above published regulatory standards. The 2008 survey analysed 193 Ayurvedic medicines bought over the internet: the prevalence of metal-containing products was 20.7%, with 21.7% for US-made and 19.5% for Indian-made products (P = .86), and 40.6% for rasa shastra medicines against 17.1% for non-rasa shastra ones. Among the metal-containing products, 75% claimed Good Manufacturing Practices, and all exceeded one or more standards for acceptable daily intake of toxic metals. The two surveys agree at about one product in five, although their sampling frames and years differ, and neither measured bhringraj products specifically. The qualitative finding — that contamination is real, repeatedly documented, and not rare enough to ignore — is what the evidence supports, and it is enough to act on.
Where the risk concentrates. Heavily in rasa shastra preparations (bhasma, sindoor-containing products), which deliberately contain processed metals and minerals as part of their pharmacology. Those are a different product class from a plain herbal powder, and the intentional cases account for the extreme values. Contamination has nonetheless been found in plain herbal products too, from soil, processing equipment or adulteration.
An honest route distinction that most pages miss. The metal concern applies chiefly to swallowed products — churna, capsules, tablets. For an oil massaged into the scalp and washed out, inorganic lead is poorly absorbed through intact skin, so the ingestion-based risk assessment does not transfer directly to a topical oil. That is not a clean bill of health — hand-to-mouth transfer is real, especially in children, and organic metal species behave differently from inorganic ones — but a scalp oil and a daily capsule are not the same exposure and it is inaccurate to present them as one.
What the surveys mean for buyers.
- Third-party heavy-metal testing of the specific batch, shown on a certificate of analysis, is direct evidence on contamination; a generic claim is not. In the 2008 survey, 75% of the metal-containing products claimed Good Manufacturing Practices, so a GMP claim alone did not mark a clean product.
- Products stating the binomial and plant part show a manufacturer that has pinned down identity; one vague about identity is unlikely to be rigorous about contaminants.
- Rasa shastra / bhasma products contain metals by design; in the 2008 survey, 40.6% of rasa shastra medicines contained metals, against 17.1% of the others.
- Products intended for children or pregnancy carry the highest stakes, for the reasons given in the pregnancy section above.
- If someone has taken imported Ayurvedic products long-term and has unexplained anaemia, abdominal pain, neuropathy or cognitive change, a blood lead level is a cheap test and the diagnosis is otherwise easily missed. See lead, mercury, arsenic and heavy metals.
Hazards Bhringraj Does Not Have
Naming what a plant is not guilty of is as much a part of accuracy as naming what it is — and a reader who has read other herb pages on this site may reasonably arrive wondering about each of these. Every item below was checked and came back clear.
- No pyrrolizidine alkaloids. The hepatotoxic PAs of the daisy family are concentrated in the tribes Senecioneae (Senecio, Petasites, coltsfoot) and Eupatorieae (boneset). Eclipta sits in Heliantheae, the sunflower tribe, and PAs are not part of its reported constituent profile. There is no duration cap on this plant for that reason.
- No aristolochic acid issue. That is the Aristolochia substitution story in some Chinese herbal products, an unrelated family and an unrelated failure mode.
- No documented hepatotoxicity. The research direction is the opposite, and Eclipta is not among the named offenders in herbal liver-injury series. The relevant caution is different: using it instead of assessment for a liver problem is the risk — see the liver page.
- No thiaminase activity of the horsetail kind, so no vitamin B1 depletion mechanism.
- No stimulant-laxative anthraquinones, so no dependence or electrolyte concern of the senna type.
- No hydroquinone-type active moiety, so it does not carry uva ursi's short-duration limit.
- No documented phototoxic case reports, despite the terthienyl chemistry — which is why the sun advice above is framed as a free precaution rather than a warning.
- No documented acute toxicity at food-level exposure. Young shoots have been eaten as an occasional potherb across South and Southeast Asia and the fresh juice used as a household remedy, without a notable acute-poisoning record. That is weak but genuine reassurance about acute toxicity — and it says nothing about concentrated extracts taken daily for months, which is a different exposure entirely.
- The common name carries no hidden safety implication. Kesharaja means "king of hair"; the ink-related regional names describe the black sap. Unlike "motherwort", whose etymology quietly means "acts on the uterus", nothing in this plant's naming smuggles in a claim about pregnancy or physiology. Checked, and clear.
What We Do Not Know
Written as findings, because absent data is a result and should not be left for the reader to infer from silence.
- No human pharmacokinetics. Absorption, bioavailability, protein binding, half-life, metabolism and elimination of wedelolactone in people: unmeasured. This is the hinge on which every systemic claim turns.
- No dermal absorption data for any Eclipta constituent. Whether anything crosses the scalp at all is unknown, in either the hopeful or the cautious direction.
- No chronic toxicology programme. No repeat-dose study of adequate duration, no reproductive or developmental toxicology, no genotoxicity battery. This page states no LD50 and no no-observed-adverse-effect level, because the figures circulating for herbal extracts are extract-specific and not comparable, and quoting one would imply a rigour that does not exist.
- No dose-finding in humans. The Ayurvedic and Chinese doses differ severalfold and neither derives from a study.
- No drug-interaction study of any kind — no P450, no P-glycoprotein, no clinical interaction trial.
- No standardisation survey of marker content across commercial oils, powders or capsules, so the delivered dose of anything is unknown even in principle.
- No pregnancy, lactation or paediatric data.
- No post-marketing surveillance. Which means the absence of case reports partly reflects the absence of anyone systematically looking — a point that cuts against complacency, though far less sharply here than for a herb used by a heavily medicated population.
- The active constituent of the rodent hair effect was never identified, so there is no compound against which the plant's flagship use could be standardised.
Key Research Papers
The named papers link their PubMed records; the remaining entries are live PubMed searches. Metadata is plain text so it can be verified; where a finding could not be tied to a verified paper, it is described and a topic search given instead — and that limitation is stated rather than hidden.
- Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS. Heavy metal content of ayurvedic herbal medicine products. JAMA, 2004;292(23):2868-73. PubMed PMID: 15598918 — Human-relevant product survey. The origin of the contamination warning: 14 (20%) of 70 products contained heavy metals.
- Saper RB, Phillips RS, Sehgal A, Khouri N, Davis RB, Paquin J, Thuppil V, Kales SN. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA, 2008;300(8):915-23 (erratum in JAMA 2008;300(14):1652). PubMed PMID: 18728265 — Product survey. The internet-sales follow-up: 20.7% of 193 products contained metals.
- Paulsen E. Contact sensitization from Compositae-containing herbal remedies and cosmetics. Contact Dermatitis, 2002;47(4):189-98. PubMed PMID: 12492516 — The standard reference for the realistic adverse event here.
- Wagner H, Geyer B, Kiso Y, Hikino H, Rao GS. Coumestans as the main active principles of the liver drugs Eclipta alba and Wedelia calendulacea. Planta Medica, 1986;(5):370-4. PubMed PMID: 3797500 — Establishes the marker chemistry that standardisation nominally rests on.
- Roy RK, Thakur M, Dixit VK. Hair growth promoting activity of Eclipta alba in male albino rats. Archives of Dermatological Research, 2008;300(7):357-64. PubMed PMID: 18478241 — Animal. Cited here for its solvents, which is what makes the taila comparison possible.
- Melo PA, Ownby CL. Ability of wedelolactone, heparin, and para-bromophenacyl bromide to antagonize the myotoxic effects of two crotaline venoms and their PLA2 myotoxins. Toxicon, 1999;37(1):199-215. PubMed PMID: 9920492 — Animal. Listed with the standing warning: snakebite is an emergency, antivenom is the treatment.
- Patel MN, Patel N, Merja A, Patel RR, Mishra M. An Integrative Approach of Neeli Bhringraj Polyherbal Hair Oil in Clinical Evaluation of Androgenetic Alopecia (Khalitya) and Premature Hair Graying (Pālitya): A Randomized, Double-Blind Clinical Study. Cureus, 2026;18(7):e111988. PubMed PMID: 42544231 — Human, multi-herb oil. Three groups, no plain-oil or placebo group; results reported as change from baseline.
- Live literature search: Eclipta and blood glucose in rodents — the basis of the antidiabetic-drug caution.
- Live literature search: Eclipta and thyroid hormones in rodents — described, not quoted; metadata unverified here.
- Live literature search: coumestans as phytoestrogens — the class basis for the hormone-sensitive caution.
- Live literature search: α-terthienyl phototoxicity.
- Live literature search: sesquiterpene lactone mix patch testing — how a Compositae allergy is actually diagnosed.
- Live literature search: lead poisoning from traditional remedies — the clinical face of the survey findings.
- Live literature search: dermal absorption of inorganic lead — why a scalp oil and a swallowed capsule are different exposures.
PubMed Topic Searches
- Eclipta toxicity and safety
- Eclipta pharmacokinetics — the gap that matters most.
- Asteraceae contact dermatitis and cross-reactivity
- Medicated-oil (taila) preparation and standardisation
- Herb-drug interaction screening methods — the studies that exist for other herbs and not this one.
- Rasa shastra and bhasma preparations
- Pyrrolizidine-alkaloid distribution within Asteraceae — the basis for clearing Eclipta.
- When to test a blood lead level
Connections
- All Herbs
- Bhringraj (Eclipta prostrata) — the main topic page, with forms, dosage and the full cautions list.
- Bhringraj for Hair Growth — why the preparation you buy is not the preparation that was studied.
- Which Bhringraj? — identity, labels and why a wedelolactone assay does not prove species.
- Liver and Other Ayurvedic Uses — the mechanism, and the polyherbal attribution trap.
- Contact Dermatitis — the realistic adverse event from any repeatedly applied Asteraceae oil.
- Seborrheic Dermatitis — the commonest real cause of an itchy, flaking scalp.
- Psoriasis — scalp psoriasis is often mistaken for dandruff and does not improve with oil.
- Lead — the metal most often found in contaminated Ayurvedic products.
- Mercury — deliberately present in some rasa shastra preparations.
- Heavy Metals — the broader picture on supplement contamination.
- Thyroid-Stimulating Hormone — the test to repeat if you start an oral preparation on thyroid medication.
- Hypothyroidism — why an unquantified thyroid signal is worth a routine check.
- Milk Thistle — another Asteraceae medicinal, and a cross-reactivity consideration.
This page is educational and is not medical advice. Bhringraj has no notable toxicity signal, and nothing here should be read as a warning against ordinary topical use. In summary: the patch test described above is read at 48 hours and again at 96 hours; there are no safety data for oral use in pregnancy or breastfeeding; anticoagulants, glucose-lowering drugs and thyroid medication are the drug classes with an unresolved or animal-based interaction signal; and in two surveys about one Ayurvedic product in five contained heavy metals. No LD50 or human dose is stated on this page, because none could be sourced — a confident figure would be a guess.